Drug

Haloperidol

Approved medicine

ClassD2-like dopamine receptor inverse agonistResearchOngoing clinical research

Also known as 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone, 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone, 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone+4 more

1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone, 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone, 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone, Haldol, Haloperidol Decanoate, Haloperidol Lactate, Haloperidolum.

RxNorm5093 ChEMBLCHEMBL54 ATCN05AD01UNIIJ6292F8L3D

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Comparison Between the Effects of Haloperidol and Dexmedetomidine on Delirium and Agitation in Patients With a Traumatic Brain Injury Admitted to the Intensive Care Unit

Clinical trial2026-06-15Primary completion · ClinicalTrials.gov

Strategies for Persistent Agitated Delirium in Palliative Care

Clinical trial2026-06-15Results expected Q4 2028 · ClinicalTrials.gov

Approval: HALOPERIDOL (ANDA214470)

Regulatory2026-06-04FDA

Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?

Clinical trial2026-04-02Results expected Q3 2028 · ClinicalTrials.gov

Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit

Clinical trial2026-03-18Results posted · ClinicalTrials.gov

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

Clinical trial2025-11-24Results expected Q4 2026 · ClinicalTrials.gov

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Clinical trial2025-11-18Results expected Q1 2027 · ClinicalTrials.gov

Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult

Clinical trial2025-05-31Primary completion · ClinicalTrials.gov

Comparison of Intravenous Haloperidol and Ondansetron Administered Intraoperatively in Reducing the Incidence of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Regional Anesthesia With Subarachnoid Block (RA-SAB)

Clinical trial2025-05-15Completed · ClinicalTrials.gov

A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

Clinical trial2025-04-29Results posted · ClinicalTrials.gov

Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department

Clinical trial2025-04-15Primary completion · ClinicalTrials.gov

Drug Safety Update: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium

Regulatory2021-12-10MHRA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Haloperidol

Aliases & brands

1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenoneHaldolHaloperidol DecanoateHaloperidol LactateHaloperidolum

RxNorm CUI

5093

ChEMBL ID

CHEMBL54

ATC codes

N05AD01

UNII

J6292F8L3D

Primary mechanism

D2-like dopamine receptor inverse agonist

Regulatory jurisdictions

fdamhra

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

D(3) dopamine receptor

DRD3 · P35462

INVERSE AGONISTD2-like dopamine receptor inverse agonist

5-hydroxytryptamine receptor 2A

HTR2A · P28223

ANTAGONISTSerotonin 2a (5-HT2a) receptor antagonist

D(2) dopamine receptor

DRD2 · P14416

INVERSE AGONISTD2-like dopamine receptor inverse agonist

D(4) dopamine receptor

DRD4 · P21917

INVERSE AGONISTD2-like dopamine receptor inverse agonist

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2026-06-04

Latest approval

2026-06-04

Authorities

FDA · MHRA

Total events

fdaU.S. Food and Drug Administration· 1 event

2026-06-04Approval

Approval: HALOPERIDOL (ANDA214470)

Evidence ↗

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2021-12-10Safety communicationSafety

Drug Safety Update: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).